Technology

AnaptysBio

$26.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (+1.87%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AnaptysBio and other stocks, options, and ETFs commission-free!

About ANAB

AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA. The listed name for ANAB is AnaptysBio, Inc. Common Stock.

CEO
Hamza Suria
Employees
89
Headquarters
San Diego, California
Founded
2005
Market Cap
665.30M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
534.91K
High Today
$27.32
Low Today
$25.81
Open Price
$26.47
Volume
461.60K
52 Week High
$31.29
52 Week Low
$12.06

Collections

ANAB Earnings

-$1.20
-$0.80
-$0.40
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 1, After Hours

You May Also Like

UCL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure